FDA relied on proprietary company data, charges Pfizer

Share this article:
Pfizer's charge that the FDA relied on proprietary company data on its Genotropin in approving rival Sandoz' human growth hormone product Omnitrope have been denied by the agency. It said Sandoz had to establish that "Omnitrope is highly similar to Genotropin without reference to proprietary data in Pfizer's Genotropin NDA."
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.